Overview
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Eligibility
Inclusion Criteria:
- • Patients 18-80 years of age with a diagnosis of a hematological malignancy
- Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies
Exclusion Criteria:
- • Patients enrolled in investigational clinical trials
- Sct for non hematologic malignancies